CS268831B2 - Method of liquid pharmaceutical agents production - Google Patents
Method of liquid pharmaceutical agents production Download PDFInfo
- Publication number
- CS268831B2 CS268831B2 CS873893A CS389387A CS268831B2 CS 268831 B2 CS268831 B2 CS 268831B2 CS 873893 A CS873893 A CS 873893A CS 389387 A CS389387 A CS 389387A CS 268831 B2 CS268831 B2 CS 268831B2
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- liquid pharmaceutical
- weight
- cephalosporin
- ppg
- ethylene oxide
- Prior art date
Links
- 239000007788 liquid Substances 0.000 title claims description 9
- 238000000034 method Methods 0.000 title claims description 5
- 238000004519 manufacturing process Methods 0.000 title claims description 3
- 239000008177 pharmaceutical agent Substances 0.000 title 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 10
- 229930186147 Cephalosporin Natural products 0.000 claims description 9
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims description 9
- 229940124587 cephalosporin Drugs 0.000 claims description 9
- 150000001780 cephalosporins Chemical class 0.000 claims description 9
- 150000002960 penicillins Chemical class 0.000 claims description 8
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 7
- 229920000642 polymer Polymers 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 229920001577 copolymer Polymers 0.000 claims description 4
- 229920001451 polypropylene glycol Polymers 0.000 description 13
- 239000006260 foam Substances 0.000 description 6
- DKOQGJHPHLTOJR-WHRDSVKCSA-N cefpirome Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 DKOQGJHPHLTOJR-WHRDSVKCSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000000654 additive Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000002518 antifoaming agent Substances 0.000 description 2
- WHRVRSCEWKLAHX-LQDWTQKMSA-N benzylpenicillin procaine Chemical compound [H+].CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 WHRVRSCEWKLAHX-LQDWTQKMSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005187 foaming Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000009516 primary packaging Methods 0.000 description 2
- 229940095783 procaine benzylpenicillin Drugs 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical group [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 229960000466 cefpirome Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940025708 injectable product Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cephalosporin Compounds (AREA)
- Manufacture Of Porous Articles, And Recovery And Treatment Of Waste Products (AREA)
- Polyethers (AREA)
- Professional, Industrial, Or Sporting Protective Garments (AREA)
- Display Devices Of Pinball Game Machines (AREA)
- Jib Cranes (AREA)
Abstract
Description
Předložený vynález se týká způsobu výroby kapalných farmaceutických přípravků na bázi derivátů cefalosporinu nebo penicilinu.The present invention relates to a process for the manufacture of liquid pharmaceutical preparations based on cephalosporin or penicillin derivatives.
Kapalné farmaceutické přípravky, které mají sklon к tvorbě pěny, a které se aplikují parenterálně, lze připravovat jen velmi obtížně a za časových ztrát a stejně obtížně a za časových ztrát lze tyto přípravky poté plnit.Také příprava vlastní aplikace je spojena s časovou ztrátou, vzhledem к tomu, že se muší vyčkat až do okamžiku rozrušení pěny. Injekční roztok, který je na svém povrchu pokryt pěnou, není možno aplikovat.Liquid pharmaceutical formulations which are prone to foaming and which are to be administered parenterally can only be prepared very difficult and at the same time and equally difficult and time-consuming to prepare. to wait until the foam breaks. A solution for injection that is covered with foam on its surface cannot be administered.
Běžné prostředky proti pěnění pro orálně aplikované farmaceutické přípravky, jako je silikonový olej nebo oktanol, jsou z toxikologických důvodů jako přísady pro parenterálně používané přípravky problematické. Kromě toho mohou tyto přísady způsobovat v injekčních roztocích zákaly. V literatuře (Blažej á další, Tenzidy 1977, str. 92) je uvedena zmínka o použití kopolymerů ethylenoxidu β propylenuxidem jako odpěňovacích přípravků v různých oblastech a také ve farmacii. Jedná se věak o zcela obecný údaj bez jakéhokoli dalěího upřesnění. .Conventional antifoams for orally administered pharmaceutical formulations, such as silicone oil or octanol, are problematic as additives for parenterally used formulations for toxicological reasons. In addition, these additives can cause turbidity in injection solutions. The literature (Blažej et al., Surfactants 1977, p. 92) mentions the use of ethylene oxide β-propyleneuxide copolymers as antifoams in various fields as well as in pharmacy. However, this is a general statement without any further specification. .
S překvapením bylo nyní zjištěno, že při použití blokového polymeru ethylenoxidu a propylenoxidu s průměrnou molekulovou hmotností 1600 až 2200 a s obsahem 5 až 15 % ethylenoxidu a 85 až 95 % hmotnostních propylenoxidu v molekule kopolymerů, lze dosáhnout rychlého zániku pěny při přípravě přípravků na bázi derivátů cefalosporinu a penicilinu.Surprisingly, it has now been found that by using a block polymer of ethylene oxide and propylene oxide having an average molecular weight of 1600 to 2200 and containing 5 to 15% ethylene oxide and 85 to 95% by weight propylene oxide in the copolymer molecule, rapid foam extinction can be achieved cephalosporin and penicillin.
Předmětem předloženého vynálezu je tudíž způsob výroby kapalných farmaceutických přípravků na bázi derivátů cefalosporinu nebo penicilinu, který spočívá v tom, že se derivát cefalosporinu nebo penicilinu rozpustí ve vodě v přítomnosti 0,00001 až 0,01 X hmotnostního blokového polymeru ethylenoxidu a propylenoxidu s průměrnou molekulovou hmotností 1600 až 2200 a s obsahem 5 až 15 % hmotnostních ethylenoxidu a 85 až 95 $ hmotnostních propylenoxidu v molekule kopolymerů, vztaženo na celkovou hmotnost kapalného farmaceutického přípravku.Accordingly, it is an object of the present invention to provide a liquid pharmaceutical formulation based on cephalosporin or penicillin derivatives, which comprises dissolving a cephalosporin or penicillin derivative in water in the presence of 0.00001-0.01% by weight ethylene oxide and propylene oxide block polymer with an average molecular weight by weight 1600 to 2200 and containing 5 to 15% by weight of ethylene oxide and 85 to 95% by weight of propylene oxide in the copolymer molecule, based on the total weight of the liquid pharmaceutical preparation.
Jako blokový kopolymer ethylenoxidu a propylenoxidu je zvláště výhodný polyethylen-polypropylenglykol 1800, který se v další části označuje také jako PPG 1800.As a block copolymer of ethylene oxide and propylene oxide, polyethylene-polypropylene glycol 1800, which is also hereinafter referred to as PPG 1800, is particularly preferred.
Zvláště výhodně se postupem podle vynálezu připravují parenterálně aplikovatelné farmaceutické přípravky na bázi derivátů cefalosporinu nebo penicilinu. Samozřejmou podmínkou je, že uvedená léčiva musí být kompatibilní s používanými blokovými polymery ethylenoxidu a propylenoxidu. Vhodnými deriváty cefalosporinu je například Cefpirom (HR 810) a vhodným derivátem penicilinu je například prokain-benzylpenicilin.Parenterally applicable pharmaceutical preparations based on cephalosporin or penicillin derivatives are particularly preferably prepared by the process according to the invention. Of course, the drugs must be compatible with the ethylene oxide and propylene oxide block polymers used. Suitable cephalosporin derivatives are, for example, Cefpirome (HR 810) and a suitable penicillin derivative is, for example, procaine-benzylpenicillin.
Kromě uvedeného postupu přípravy kapalných farmaceutických přípravků, který je předmětem předloženého vynálezu, lze požadovaného snížení pěnivosti při přípravě kapalných farmaceutických přípravků na bázi derivátů cefalosporinu nebo penicilinu dosáhnout alternativně také tak, že se blokový polymer ethylenoxidu a propylenoxidu charakterizovaný shora nanese na pevnou účinnou látku nebo se účinná látka polymerem impregnuje.In addition to the present process for the preparation of liquid pharmaceutical preparations of the present invention, the desired foam reduction in the preparation of liquid pharmaceutical preparations based on cephalosporin or penicillin derivatives may alternatively also be achieved by applying the ethylene oxide and propylene oxide block polymer described above to the solid active substance or the active substance impregnates the polymer.
Vynález blíže objasňují následující příklady, které však rozsah vynálezu v žádném směru neomezují. ( The following examples illustrate the invention but do not limit it in any way. (
PřikladlHe did
Přípravek pro injekční účely obsahující 1,23 g sulfátu Cefpiromu (HR 810) a 0,22 g bezvodého uhličitanu sodného vytvoří po rozpuštění v 10 ml vody pěnu, která zůstane beze změny minimálně 5 minut.Injectable product containing 1.23 g of Cefpirom sulphate (HR 810) and 0.22 g of anhydrous sodium carbonate forms a foam after dissolution in 10 ml of water which remains unchanged for at least 5 minutes.
Použije-li se к rozpuštění místo 10 ml vody stejného množství vody, ke kterému se v průběhu rozpouštění 1,23 g sulfátu Cefpiromu (HR 810) přidá 0,0005 % hmotnostního, tj. 0,006 g polyethylen-polypropylenglykolu 1800, pak pěna zmiží prakticky ihned po rozpuštění.If, instead of 10 ml of water, the same amount of water is used to dissolve, to which 0.0005% by weight, i.e. 0.006 g of polyethylene-polypropylene glycol 1800, is added during the dissolution of 1.23 g of Cefpirom sulfate (HR 810), immediately after dissolution.
Stejného účinku lze dosáhnout, jestliže se přibližně ekvivalentní množství PPG 1800 nanese na jednotlivé nebo všechny pevné složky směsi, například vysrážením v přítomnosti PPG 1800, přidáním PPG 1800 к promývacímu roztoku vysrážených pevných látek, nastříkáním roztoku PPG 1800 na pevné látky a následujícím vysušením.The same effect can be achieved if approximately equivalent amounts of PPG 1800 are applied to individual or all solid components of the mixture, for example by precipitation in the presence of PPG 1800, adding PPG 1800 to the precipitated solids washing solution, spraying the PPG 1800 solution onto the solids and subsequently drying.
Kromě toho lze protipěnového účinku PPG 1800 dosáhnout impregnací primárních obalových prostředků (například injekčních lahviček nebo/a zátek injekčních lahviček) pomocí PPG 1800.In addition, the antifoam effect of PPG 1800 can be achieved by impregnating primary packaging means (e.g., vials and / or vial stoppers) with PPG 1800.
Příklad 2Example 2
Suspenze prokain-benzylpenicilinu obsahující 300 000 m.j./ml se dá vzhledem к silnému pěnění plnit Jen velmi obtížně. Suspenze, která v důsledku pěny nabude na svém objemu, se Již nedá naplnit do injekčních lahví, které Jsou určeny к primárnímu balení. Již 0,001 % (% hmotnostní) přídavek PPG 1800 působí proti tvorbě pěny, jak je patrno z následující tabulky: .The procaine-benzylpenicillin suspension containing 300,000 IU / ml is difficult to fill due to the strong foaming. The suspension, which becomes foamed due to the foam, can no longer be filled into injection bottles intended for primary packaging. Already 0.001% (w / w) of PPG 1800 additive is anti - foam, as can be seen from the following table:.
Tabulka suspenzeSuspension table
Hustota fg/mfl minuty po L J 60 minut po suspendování suspendování bez PPG 1800 s přídavkem 0,001 % PPG 1800 s přídavkem 0,01 % PPG 1800Density fg / mfl minutes after LJ 60 minutes after suspension suspending without PPG 1800 with addition of 0.001% PPG 1800 with addition of 0.01% PPG 1800
1,0121,001,0121,00
1,0411,0551,0411,055
1,0531,0581,0531,058
Claims (1)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3618217A DE3618217C1 (en) | 1986-05-30 | 1986-05-30 | Use of ethylene oxide-propylene oxide block polymers for foam control in liquid medicinal preparations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CS389387A2 CS389387A2 (en) | 1989-08-14 |
| CS268831B2 true CS268831B2 (en) | 1990-04-11 |
Family
ID=6301946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS873893A CS268831B2 (en) | 1986-05-30 | 1987-05-28 | Method of liquid pharmaceutical agents production |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP0247584B1 (en) |
| JP (1) | JPS62289529A (en) |
| KR (1) | KR970005334B1 (en) |
| AT (1) | ATE59783T1 (en) |
| AU (1) | AU599658B2 (en) |
| CA (1) | CA1322170C (en) |
| CS (1) | CS268831B2 (en) |
| DD (1) | DD266026A5 (en) |
| DE (2) | DE3618217C1 (en) |
| DK (1) | DK167211B1 (en) |
| ES (1) | ES2036544T3 (en) |
| FI (1) | FI88871C (en) |
| GR (1) | GR3001614T3 (en) |
| HK (1) | HK86895A (en) |
| HU (1) | HU196311B (en) |
| IE (1) | IE60658B1 (en) |
| IL (1) | IL82700A (en) |
| MA (1) | MA20988A1 (en) |
| MY (1) | MY102448A (en) |
| NO (1) | NO175844C (en) |
| NZ (1) | NZ220479A (en) |
| PH (1) | PH24473A (en) |
| PT (1) | PT84970B (en) |
| ZA (1) | ZA873878B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1475098B1 (en) * | 2002-01-18 | 2015-08-05 | Asahi Kasei Pharma Corporation | High-concentration preparation of soluble thrombomodulin |
| DE102010048948A1 (en) | 2010-10-19 | 2011-12-29 | Clariant International Ltd. | Aqueous defoamer emulsion, useful e.g. as protective colloids, comprises oil phase, emulsifiers, and water-soluble or -swellable, crosslinked copolymers containing e.g. acrylamidoalkylsulfonic acid- and cyclic N-vinylcarboxamide-compounds |
| DE102018220624A1 (en) * | 2018-11-29 | 2020-06-04 | B. Braun Melsungen Ag | Aqueous composition, especially for the treatment of mucous membranes and / or wounds |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3142628A (en) * | 1964-07-28 | Process of reducing foam in submerges | ||
| DE925375C (en) * | 1949-08-03 | 1955-03-21 | Upjohn Co | Process for the production of a procaine-penicillin-G preparation |
| US2937104A (en) * | 1958-08-18 | 1960-05-17 | Stephan John Thomas | Polymeric alkylene-oxide defoamer material for alkaline aqueous adhesive solutions and the like |
| JPS5416568B2 (en) * | 1972-09-29 | 1979-06-23 | ||
| US4104033A (en) * | 1975-09-12 | 1978-08-01 | Drew Chemical Corporation | Foam prevention in sodium carbonate crystallization |
| GB2067533B (en) * | 1980-01-15 | 1983-07-13 | Exxon Research Engineering Co | Defoaming acid gas scrubbing solutions |
| US4533542A (en) * | 1983-08-22 | 1985-08-06 | Eli Lilly And Company | Pharmaceutical compositions for storage in plastic containers and process therefor |
-
1986
- 1986-05-30 DE DE3618217A patent/DE3618217C1/en not_active Expired
-
1987
- 1987-05-26 ES ES198787107677T patent/ES2036544T3/en not_active Expired - Lifetime
- 1987-05-26 AT AT87107677T patent/ATE59783T1/en not_active IP Right Cessation
- 1987-05-26 DE DE8787107677T patent/DE3767215D1/en not_active Expired - Lifetime
- 1987-05-26 EP EP87107677A patent/EP0247584B1/en not_active Expired - Lifetime
- 1987-05-27 MY MYPI87000742A patent/MY102448A/en unknown
- 1987-05-28 MA MA21227A patent/MA20988A1/en unknown
- 1987-05-28 DD DD87303274A patent/DD266026A5/en not_active IP Right Cessation
- 1987-05-28 NZ NZ220479A patent/NZ220479A/en unknown
- 1987-05-28 CS CS873893A patent/CS268831B2/en not_active IP Right Cessation
- 1987-05-28 FI FI872381A patent/FI88871C/en not_active IP Right Cessation
- 1987-05-28 PH PH35316A patent/PH24473A/en unknown
- 1987-05-29 ZA ZA873878A patent/ZA873878B/en unknown
- 1987-05-29 JP JP62131929A patent/JPS62289529A/en active Pending
- 1987-05-29 IE IE142987A patent/IE60658B1/en not_active IP Right Cessation
- 1987-05-29 KR KR1019870005376A patent/KR970005334B1/en not_active Expired - Lifetime
- 1987-05-29 CA CA000538397A patent/CA1322170C/en not_active Expired - Lifetime
- 1987-05-29 IL IL82700A patent/IL82700A/en not_active IP Right Cessation
- 1987-05-29 PT PT84970A patent/PT84970B/en unknown
- 1987-05-29 AU AU73643/87A patent/AU599658B2/en not_active Expired
- 1987-05-29 HU HU872489A patent/HU196311B/en unknown
- 1987-05-29 NO NO872265A patent/NO175844C/en unknown
- 1987-05-29 DK DK274787A patent/DK167211B1/en not_active IP Right Cessation
-
1991
- 1991-03-15 GR GR91400062T patent/GR3001614T3/en unknown
-
1995
- 1995-06-01 HK HK86895A patent/HK86895A/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR2608942B1 (en) | PROCESS FOR THE PREPARATION OF COLLOIDAL DISPERSIBLE SYSTEMS OF A SUBSTANCE, IN THE FORM OF NANOCAPSULES | |
| JPH0641483B2 (en) | Stable polymer dispersion and process for making the same | |
| HU216546B (en) | Moulding or spinning material containig cellulose, process for producing thereof and process for producing formbodies using them | |
| KR940018086A (en) | Pharmaceutical Compositions Containing Nanocapsules | |
| DE68927669D1 (en) | METHOD FOR THE PRODUCTION OF MICRO-CARRIERS THAT CAN BE DILUTED IN SOLVENTS | |
| PL176726B1 (en) | Hydrogen peroxide containing preparation | |
| US4836939A (en) | Stable expandable foam & concentrate & method | |
| PT89534B (en) | PROCESS FOR THE PREPARATION OF ANTICOAGULANT PHARMACEUTICAL COMPOSITIONS CONTAINING AS ACTIVE INGREDIENT PROTEIN C OR PROTEIN C ACTIVATED COMBINED WITH HEPARIN | |
| SI9400087B (en) | Novel process for the preparation of cetrorelix lyophilisate | |
| CA2187898A1 (en) | Controlled release biodegradable microspheres and method of preparation | |
| DE2952287A1 (en) | METHOD FOR PRODUCING A POLYSILOXANE BLOCK POLYMERISATE AND THE USE THEREOF AS A FOAM INHIBITOR | |
| EP0504952A1 (en) | Stable liquid amidoperoxyacid bleach | |
| US3172816A (en) | Method of increasing the oil solubility of compounds and products thereof | |
| DE69220442D1 (en) | HEPARINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF | |
| CS268831B2 (en) | Method of liquid pharmaceutical agents production | |
| CA1334378C (en) | Stabilizing packaged iodophor and minimining leaching of iodine through packaging | |
| ATE327823T1 (en) | METHOD FOR PRODUCING COLLOIDAL PARTICLES WHICH ARE IN THE FORM OF NANOCAPSULES | |
| JPH0749373B2 (en) | Method for producing aqueous liquid preparation containing organic acid as active ingredient | |
| DE69321711T2 (en) | Stable aqueous nonionic surfactant emulsions | |
| KR910000161A (en) | Intravenous solution with rapid action manifestation | |
| GB2047257A (en) | Water Soluble Polymeric Material | |
| MXPA01012861A (en) | Method for the production of liquid cleaning agent or detergent compositions. | |
| RU1635330C (en) | Plasma-substituting solution "polyoxidine" for treating shock and blood losses | |
| CZ301889A3 (en) | process for preparing aqueous emulsions of high-molecular polyorganosiloxanes | |
| TH2698B (en) | Bleaching agent components |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| IF00 | In force as of 2000-06-30 in czech republic | ||
| MK4A | Patent expired |
Effective date: 20020528 |